Available
Esketamine (Spravato)
FDA-approved nasal spray for TRD, administered under clinical supervision.
Treatment-Resistant Depression · Emerging Research
Where the science stands on psychedelic-assisted depression treatment
A plain-language look at the research, the current regulatory process, and what's actually available today for depression that hasn't responded to standard treatment.
2–3M
Estimated Americans living with treatment-resistant depression
2+
Antidepressant courses typically tried before a TRD diagnosis applies
Days
Reported timeframe for symptom change in some psychedelic-assisted trials, vs. weeks for standard antidepressants
Approaches
Current and emerging approaches
Available
Ketamine infusion therapy
Used off-label at specialized clinics; not FDA-approved specifically for depression.
Available
TMS & accelerated TMS
Non-drug, device-based approaches including newer accelerated protocols.
In Trials
Psilocybin-assisted therapy
Synthetic psilocybin given in a supervised clinical setting alongside psychological support. Late-stage trials report significant TRD improvement. Not yet FDA-approved.
In Trials
MDMA-like compounds
Related compounds in earlier-stage trials for PTSD, with some overlap into mood-disorder research.
Regulation
The regulatory landscape
2022–23
Early controlled trials
Randomized studies begin reporting measurable symptom change in supervised settings.
2025–26
Late-stage trial results
Larger confirmatory trials report outcomes in treatment-resistant populations.
2026
Priority review pathway
Regulatory pathways designed to speed evaluation of promising therapies come into play.
Ahead
Potential first approval
If data holds, a first regulated approval for a psychedelic-assisted protocol becomes possible. Nothing is approved on this basis yet.
Updates
Get notified when this changes
This is a developing story. Leave your email and we'll let you know when there's real news — not more speculation.
No spam. Occasional updates only, when something material changes.